Why did TITANBIO.BO stock fall 80.00% pre-market?

The sharp drop reflects heavy pre-market selling and a large gap from previous close of **INR 1,301.70** to **INR 260.34**. No confirmed public filing explained the move at publication; the decline looks company-specific with significant volume.

What is Meyka AI's short-term forecast for TITANBIO.BO stock?

Meyka AI's forecast model projects a **Quarterly** price of **INR 587.65**, implying **125.69%** upside from **INR 260.34**. These model projections are not guarantees and assume no further adverse corporate developments.

Should I trade or hold TITANBIO.BO stock after this drop?

Meyka AI assigns a **B (HOLD)** grade. Traders should prioritise confirmed news and liquidity. Long-term investors should weigh balance-sheet strength against rich valuation and event risk before adding exposure.

What valuation metrics matter for TITANBIO.BO stock?

Key metrics include **PE 53.46**, PB **7.39**, EPS **INR 5.57**, and current ratio **2.78**. These show profitability and liquidity, but high market multiples versus sector peers increase valuation risk.

IN Stocks

TITANBIO.BO stock down 80.00% pre-market on BSE: top losers watch INR 260.34 risk

ByDanny Kontos February 21, 2026February 21, 2026

TITANBIO.BO stock fell 80.00% in pre-market trade on BSE to INR 260.34, making Titan Biotech Limited (TITANBIO.BO) one of today’s clear top losers. Volume surged to 689,025 shares versus an average of 10,294, a 15.38x spike that signals forced selling or heavy exit flows. The stock opened at INR 259.00 against a previous close of INR 1,301.70, creating a visible gap. This update uses Meyka AI, an AI-powered market analysis platform, to link market moves to fundamentals, technicals, and short-term forecasts.